Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Chen

Showing results (471-480 of 482) with videos related to

Pageof 49
Sort By:
Journal of Synchrotron Radiation|April 19, 2008
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034Vincent Madison, Andrew J Prongay, Zhuyan Guo, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung CancerHaniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Journal of Medicinal Chemistry|April 21, 2007
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimizationAndrew J Prongay, Zhuyan Guo, Nanhua Yao, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Targetable treatment resistance in thyroid cancer with clonal hematopoiesisVera Tiedje, Pablo Sánchez Vela, Julie L Yang, et al.
Cancer Discovery|April 30, 2026
Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute LeukemiasTakeshi Fujino, Jennifer Lewis, Bingyi Chen, et al.
Journal of Medicinal Chemistry|September 29, 2006
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infectionSrikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 17, 2025
Capacity building in dementia research: insights from the World Young Leaders in DementiaFlorentina Morello-Garcia, Nicolas Corvalan, Jorge Llibre-Guerra, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthFlorentina Morello Garcia, Nicolas Corvalan, Micaela Maria Arruabarrena, et al.
Cell|March 31, 2026
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapyZeda Zhang, Yu-Jui Ho, Xin Fang, et al.
Plos One|July 18, 2017
Tales of diversity: Genomic and morphological characteristics of forty-six Arthrobacter phagesKaren K Klyczek, J Alfred Bonilla, Deborah Jacobs-Sera, et al.
Pageof 49

Showing results (471-480 of 482) with videos related to

Sort By:
Pageof 49
Journal of Synchrotron Radiation|April 19, 2008
Key steps in the structure-based optimization of the hepatitis C virus NS3/4A protease inhibitor SCH503034Vincent Madison, Andrew J Prongay, Zhuyan Guo, et al.
Cancer Discovery|July 8, 2024
Mechanisms of Response and Tolerance to Active RAS Inhibition in KRAS-Mutant Non-Small Cell Lung CancerHaniel A Araujo, Ximo Pechuan-Jorge, Teng Zhou, et al.
Journal of Medicinal Chemistry|April 21, 2007
Discovery of the HCV NS3/4A protease inhibitor (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3- [2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (Sch 503034) II. Key steps in structure-based optimizationAndrew J Prongay, Zhuyan Guo, Nanhua Yao, et al.
Biorxiv : the Preprint Server for Biology|October 17, 2024
Targetable treatment resistance in thyroid cancer with clonal hematopoiesisVera Tiedje, Pablo Sánchez Vela, Julie L Yang, et al.
Cancer Discovery|April 30, 2026
Development of CAR T cells Targeting a Surface RNA Binding Protein for the Treatment of Acute LeukemiasTakeshi Fujino, Jennifer Lewis, Bingyi Chen, et al.
Journal of Medicinal Chemistry|September 29, 2006
Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]- 3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infectionSrikanth Venkatraman, Stéphane L Bogen, Ashok Arasappan, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 17, 2025
Capacity building in dementia research: insights from the World Young Leaders in DementiaFlorentina Morello-Garcia, Nicolas Corvalan, Jorge Llibre-Guerra, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|December 23, 2025
Public HealthFlorentina Morello Garcia, Nicolas Corvalan, Micaela Maria Arruabarrena, et al.
Cell|March 31, 2026
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapyZeda Zhang, Yu-Jui Ho, Xin Fang, et al.
Plos One|July 18, 2017
Tales of diversity: Genomic and morphological characteristics of forty-six Arthrobacter phagesKaren K Klyczek, J Alfred Bonilla, Deborah Jacobs-Sera, et al.
Pageof 49